ALPMY News Alert Astellas Pharma Inc (ALPMY) 14.6500 09/21/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 21, 2014 at 1:07 AM

Astellas Pharma Inc (ALPMY) 14.6500 $ALPMY

Medivation-Astellas' Xtandi's Label Expanded by FDA - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Sep 11, 5:35PM CDT
Xtandi's label expansion into the pre-chemo population is a major boost for Medivation (MDVN).

Astellas' Antifungal Under FDA Review, Response by Mar 2015 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:50PM CDT
Astellas (ALPMY) and partner Basilea's new drug application for isavuconazole is under FDA review for invasive aspergillosis and invasive mucormycosis.

Astellas-Basilea's Isavuconazole Accepted for EU Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:30PM CDT
Astellas Pharma, Inc. (ALPMY) and Basilea's isavuconazole has been accepted for review in the EU for the treatment of invasive aspergillosis and mucormycosis.

AVEO Pharmaceuticals Posts Narrower-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 8:30AM CDT
AVEO Pharmaceuticals reported a second-quarter 2014 loss of 35 cents per share.

Medivation Jumps on Q2 Earnings Beat, Outlook Encourages - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 11:10AM CDT
Medivation Inc. (MDVN) posted earnings of 60 cents per share.

Astellas Up on Pipeline Update, Oncology in Focus (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 3:07PM CDT
Astellas Pharma, Inc. (ALPMY) provided a comprehensive overview of its initiatives towards innovation, research and development and its corporate strategy.

Astellas' Isavuconazole Gets QIDP for Invasive Candidiasis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 4:50PM CDT
Astellas Pharma, Inc.'s (ALPMY) isavuconazole received Qualified Infectious Disease Product (QIDP) designation from the FDA for treating invasive candidiasis.

Astellas Up on Pipeline Update, Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 2:03PM CDT
Astellas Pharma, Inc.'s (ALPMY) shares gained 2.5% following the company's update on its pipeline and corporate strategy late last week.

Astellas Seeks FDA Nod for Fungal Infection Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 4:30PM CDT
Astellas Pharma, Inc. (ALPMY) has filed an NDA with the FDA for isavuconazole for the treatment of invasive aspergillosis and mucormycosis.

ARIAD Candidate in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 5:10PM CDT
ARIAD started phase II pivotal study on AP26113 for non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer's Xalkori (crizotinib).

AstraZeneca's Forxiga Approved in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 3:45PM CDT
AstraZeneca announced that its type II diabetes drug, Forxiga, has been approved by the Japanese Ministry of Health, Labour and Welfare.

Japan Approves Medivation/Astellas' Xtandi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 12:50PM CDT
Prostate cancer treatment, Xtandi, which is already approved in more than 35 countries is now approved in Japan.

AVEO Regains AV-203 Rights from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 5:10PM CDT
AVEO Oncology (AVEO) recently announced that it has regained worldwide rights of candidate AV-203 from Biogen Idec (BIIB).

Medivation, Inc: Fast Growing Drugs That May Become Blockbusters
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 21, 1:30PM CDT
Blockbuster status -- the gold medal term awarded to therapies racking up sales of more than $1 billion per year -- is the Holy Grail for drug developers. Arguably, it's the chance to discover blockbusters that fuels industry R&D spend and...

Medivation-Astellas Seek Xtandi Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 3:20PM CDT
The companies are looking to get Xtandi approved for the chemo-naive patient population.

AVEO Q4 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 8:10AM CDT
AVEO Pharmaceuticals reported a fourth quarter 2013 loss of 32 cents per share.

Was Medivation's Quarter a Disaster?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 03, 5:30PM CST
Medivation's sell-off last week reflects investor disappointment in guidance for sales of Xtandi, a prostate cancer drug prescribed to patients who fail to respond to chemotherapy. Sales of Xtandi jumped double digit percentages...

Medivation Swings to Earnings in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:30AM CST
Xtandi's approval in the pre-chemo setting would boost sales significantly.

Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 19, 8:27AM CST
The Medicines Co. was also in the news with an FDA advisory panel refusing to back the company's antiplatelet agent, Cangrelor.

Primco Files Preliminary Form 14c to Increase Authorized Shares
PR Newswire - Tue Feb 18, 11:30PM CST
Primco Management Inc. (OTCQB: PMCM), a fully integrated multi-media entertainment and real estate development company today announced that the Company has filed Form 14c, as required by the Securities and Exchange Commission, informing shareholders of an increase in the authorized to 25 billion common shares as a reserve requirement for possible future conversion issuances, in accordance with contractual obligations to convertible debt holders based on the recent low stock price of $0.0001. The increase will further allow Primco to have sufficient shares available for equity funding, and/or for potential acquisitions which the Board of Directors may determine is in the best interest of the shareholders.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

IEHP's Wellness Center Launch Faces Delay in California

Unexpected Delay for IEHP's Community Hub Straight outta Rancho Cucamonga, we've got some news that'll have folks in San Bernardino holding their breath a little longer. The Inland Empire Health Plan (or IEHP if you're part of the 1.4 million served by them) had folks pumped for their new Community Wellness Center. But guess what? They had to slam the brakes on the grand...

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Windward Bio Surges 68% in Nasdaq Debut

By Ryan Hughes Updated Nov 13, 2026 Category News Views 243

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

LaserAway Expands to 244 Clinics Over 20 Years

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...